Eloxx Pharmaceuticals, Inc.’s (NASDAQ:ELOX) Quiet Period To Expire on July 20th

Eloxx Pharmaceuticals’ (NASDAQ:ELOX) quiet period will expire on Monday, July 20th. Eloxx Pharmaceuticals had issued 2,975,000 shares in its IPO on June 9th. The total size of the offering was $32,725,000 based on an initial share price of $11.00. During the company’s quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Eloxx Pharmaceuticals Stock Down 4.5%

ELOX stock opened at $12.02 on Friday. Eloxx Pharmaceuticals has a twelve month low of $11.41 and a twelve month high of $17.50. The firm has a 50 day moving average of $17.49. The company has a market capitalization of $8.29 million, a price-to-earnings ratio of -0.79 and a beta of -1,891.27.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc, formerly known as Sevion Therapeutics Inc, is based in WALTHAM, United States.